302 related articles for article (PubMed ID: 20818833)
1. Population pharmacokinetics of tapentadol immediate release (IR) in healthy subjects and patients with moderate or severe pain.
Xu XS; Smit JW; Lin R; Stuyckens K; Terlinden R; Nandy P
Clin Pharmacokinet; 2010 Oct; 49(10):671-82. PubMed ID: 20818833
[TBL] [Abstract][Full Text] [Related]
2. Population Pharmacokinetic Modeling of Tapentadol Extended Release (ER) in Healthy Subjects and Patients with Moderate or Severe Chronic Pain.
Huntjens DR; Liefaard LC; Nandy P; Drenth HJ; Vermeulen A
Clin Drug Investig; 2016 Mar; 36(3):213-23. PubMed ID: 26798023
[TBL] [Abstract][Full Text] [Related]
3. Comparative pharmacokinetics and bioavailability of tapentadol following oral administration of immediate- and prolonged-release formulations.
Göhler K; Brett M; Smit JW; Rengelshausen J; Terlinden R
Int J Clin Pharmacol Ther; 2013 Apr; 51(4):338-48. PubMed ID: 23357834
[TBL] [Abstract][Full Text] [Related]
4. Dose conversion between tapentadol immediate and extended release for low back pain.
Etropolski MS; Okamoto A; Shapiro DY; Rauschkolb C
Pain Physician; 2010; 13(1):61-70. PubMed ID: 20119464
[TBL] [Abstract][Full Text] [Related]
5. Tapentadol hydrochloride: a centrally acting oral analgesic.
Wade WE; Spruill WJ
Clin Ther; 2009 Dec; 31(12):2804-18. PubMed ID: 20110020
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic evaluation of tapentadol extended-release tablets in healthy subjects.
Zannikos PN; Smit JW; Stahlberg HJ; Wenge B; Hillewaert VM; Etropolski MS
J Opioid Manag; 2013; 9(4):291-300. PubMed ID: 24353023
[TBL] [Abstract][Full Text] [Related]
7. Quantifying the Exposure of Tapentadol Extended Release in Japanese Patients with Cancer Pain and Bridging Tapentadol Pharmacokinetics Across Populations Using a Modeling Approach.
Zhang L; Yan X; Nobe S; Zannikos P; Etropolski M; Nandy P
Clin Drug Investig; 2017 Mar; 37(3):273-283. PubMed ID: 27853999
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of losmapimod in healthy subjects and patients with rheumatoid arthritis and chronic obstructive pulmonary diseases.
Yang S; Lukey P; Beerahee M; Hoke F
Clin Pharmacokinet; 2013 Mar; 52(3):187-98. PubMed ID: 23254770
[TBL] [Abstract][Full Text] [Related]
9. Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I-III Clinical Trials.
Klünder B; Mittapalli RK; Mohamed MF; Friedel A; Noertersheuser P; Othman AA
Clin Pharmacokinet; 2019 Aug; 58(8):1045-1058. PubMed ID: 30945116
[TBL] [Abstract][Full Text] [Related]
10. Tapentadol immediate release for the relief of moderate-to-severe acute pain.
Hartrick CT
Expert Opin Pharmacother; 2009 Nov; 10(16):2687-96. PubMed ID: 19795998
[TBL] [Abstract][Full Text] [Related]
11. Tapentadol immediate release: a review of its use in the treatment of moderate to severe acute pain.
Frampton JE
Drugs; 2010 Sep; 70(13):1719-43. PubMed ID: 20731478
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and tolerability of multiple-dose tapentadol immediate release for the relief of acute pain following orthopedic (bunionectomy) surgery .
Stegmann JU; Weber H; Steup A; Okamoto A; Upmalis D; Daniels S
Curr Med Res Opin; 2008 Nov; 24(11):3185-96. PubMed ID: 18851776
[TBL] [Abstract][Full Text] [Related]
13. Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind study.
Hale M; Upmalis D; Okamoto A; Lange C; Rauschkolb C
Curr Med Res Opin; 2009 May; 25(5):1095-104. PubMed ID: 19301989
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychotic.
Samtani MN; Vermeulen A; Stuyckens K
Clin Pharmacokinet; 2009; 48(9):585-600. PubMed ID: 19725593
[TBL] [Abstract][Full Text] [Related]
15. Tapentadol immediate release versus oxycodone immediate release for treatment of acute low back pain.
Biondi D; Xiang J; Benson C; Etropolski M; Moskovitz B; Rauschkolb C
Pain Physician; 2013; 16(3):E237-46. PubMed ID: 23703422
[TBL] [Abstract][Full Text] [Related]
16. Memantine pharmacotherapy: a naturalistic study using a population pharmacokinetic approach.
Kornhuber J; Kennepohl EM; Bleich S; Wiltfang J; Kraus T; Reulbach U; Meineke I
Clin Pharmacokinet; 2007; 46(7):599-612. PubMed ID: 17596105
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients.
Hennig S; Wainwright CE; Bell SC; Miller H; Friberg LE; Charles BG
Clin Pharmacokinet; 2006; 45(11):1099-114. PubMed ID: 17048974
[TBL] [Abstract][Full Text] [Related]
18. Tapentadol - A representative of a new class of MOR-NRI analgesics.
Zajączkowska R; Przewłocka B; Kocot-Kępska M; Mika J; Leppert W; Wordliczek J
Pharmacol Rep; 2018 Aug; 70(4):812-820. PubMed ID: 29921501
[TBL] [Abstract][Full Text] [Related]
19. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
Zhou H; Mayer PR; Wajdula J; Fatenejad S
J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
[TBL] [Abstract][Full Text] [Related]
20. Effects of acetaminophen, naproxen, and acetylsalicylic acid on tapentadol pharmacokinetics: results of two randomized, open-label, crossover, drug-drug interaction studies.
Smit JW; Oh C; Rengelshausen J; Terlinden R; Ravenstijn PG; Wang SS; Upmalis D; Mangold B
Pharmacotherapy; 2010 Jan; 30(1):25-34. PubMed ID: 20030470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
